Ibrutinib appears safe, effective against chronic lymphocytic leukemia Oncology Nurse Advisor As explained in an ASH statement, primary treatment for CLL includes a combined chemotherapy-based regimen with fludarabine and cyclophosphamide, along with the immune therapy rituximab. Rituximab is generally not well-tolerated among elderly ... |
